Tominersen + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease
Trial Timeline
Feb 3, 2023 → Apr 1, 2027
NCT ID
NCT05686551About Tominersen + Placebo
Tominersen + Placebo is a phase 2 stage product being developed by Roche for Huntington Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05686551. Target conditions include Huntington Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05686551 | Phase 2 | Active |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 77 |
| Votoplam | Novartis | Phase 2 | 52 |
| Branaplam + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |
| RO7234292 (RG6042) | Roche | Phase 3 | 77 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| RO7234292 + Placebo | Roche | Phase 3 | 77 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| Dextromethorphan + Dimebon + Dextromethorphan | Pfizer | Phase 1 | 32 |
| Dimebon | Pfizer | Phase 3 | 76 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 76 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Riluzole | Sanofi | Phase 3 | 76 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 74 |